Diagnosing the decline in pharmaceutical R&D efficiency
Top Cited Papers
- 1 March 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 11 (3), 191-200
- https://doi.org/10.1038/nrd3681
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerThe New England Journal of Medicine, 2011
- High-throughput crystallography for structural genomicsCurrent Opinion in Structural Biology, 2009
- Pharmaceutical R&D: the road to positive returnsNature Reviews Drug Discovery, 2009
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- Why has R&D productivity declined in the pharmaceutical industry?Expert Opinion on Drug Discovery, 2006
- Multicomponent therapeutics for networked systemsNature Reviews Drug Discovery, 2005
- The role of the medicinal chemist in drug discovery — then and nowNature Reviews Drug Discovery, 2004
- Post-genome integrative biology: so that’s what they call clinical scienceClinical Medicine, 2001
- Drug innovation—what's slowing it down?Nature, 1980